Cargando…

PET/CT planning during chemoradiotherapy for esophageal cancer

PURPOSE: To evaluate the usefulness of positron emission tomography/computed tomography (PET/CT) for field modification during radiotherapy in esophageal cancer. MATERIALS AND METHODS: We conducted a retrospective study on 33 patients that underwent chemoradiotherapy (CRT). Pathologic findings were...

Descripción completa

Detalles Bibliográficos
Autores principales: Seol, Ki Ho, Lee, Jeong Eun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society for Radiation Oncology 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3977129/
https://www.ncbi.nlm.nih.gov/pubmed/24724049
http://dx.doi.org/10.3857/roj.2014.32.1.31
_version_ 1782310385356898304
author Seol, Ki Ho
Lee, Jeong Eun
author_facet Seol, Ki Ho
Lee, Jeong Eun
author_sort Seol, Ki Ho
collection PubMed
description PURPOSE: To evaluate the usefulness of positron emission tomography/computed tomography (PET/CT) for field modification during radiotherapy in esophageal cancer. MATERIALS AND METHODS: We conducted a retrospective study on 33 patients that underwent chemoradiotherapy (CRT). Pathologic findings were squamous cell carcinoma in 32 patients and adenocarcinoma in 1 patient. All patients underwent PET/CT scans before and during CRT (after receiving 40 Gy and before a 20 Gy boost dose). Response evaluation was determined by PET/CT using metabolic tumor volume (MTV), total glycolytic activity (TGA), MTV ratio (rMTV) and TGA ratio (rTGA), or determined by CT. rMTV and rTGA were reduction ratio of MTV and TGA between before and during CRT, respectively. RESULTS: Significant decreases in MTV (MTV(2.5): mean 70.09%, p < 0.001) and TGA (TGA(2.5): mean 79.08%, p<0.001) were found between before and during CRT. Median rMTV(2.5) was 0.299 (range, 0 to 0.98) and median rTGA(2.5) was 0.209 (range, 0 to 0.92). During CRT, PET/CT detected newly developed distant metastasis in 1 patient, and this resulted in a treatment strategy change. At a median 4 months (range, 0 to 12 months) after completion of CRT, 8 patients (24.2%) achieved clinically complete response, 11 (33.3%) partial response, 5 (15.2%) stable disease, and 9 (27.3%) disease progression. SUV(max) (p = 0.029), rMTV(50%) (p = 0.016), rMTV(75%) (p = 0.023) on intra-treatment PET were found to correlate with complete clinical response. CONCLUSION: PET/CT during CRT can provide additional information useful for radiotherapy planning and offer the potential for tumor response evaluation during CRT. rMTV(50%) during CRT was found to be a useful predictor of clinical response.
format Online
Article
Text
id pubmed-3977129
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher The Korean Society for Radiation Oncology
record_format MEDLINE/PubMed
spelling pubmed-39771292014-04-10 PET/CT planning during chemoradiotherapy for esophageal cancer Seol, Ki Ho Lee, Jeong Eun Radiat Oncol J Original Article PURPOSE: To evaluate the usefulness of positron emission tomography/computed tomography (PET/CT) for field modification during radiotherapy in esophageal cancer. MATERIALS AND METHODS: We conducted a retrospective study on 33 patients that underwent chemoradiotherapy (CRT). Pathologic findings were squamous cell carcinoma in 32 patients and adenocarcinoma in 1 patient. All patients underwent PET/CT scans before and during CRT (after receiving 40 Gy and before a 20 Gy boost dose). Response evaluation was determined by PET/CT using metabolic tumor volume (MTV), total glycolytic activity (TGA), MTV ratio (rMTV) and TGA ratio (rTGA), or determined by CT. rMTV and rTGA were reduction ratio of MTV and TGA between before and during CRT, respectively. RESULTS: Significant decreases in MTV (MTV(2.5): mean 70.09%, p < 0.001) and TGA (TGA(2.5): mean 79.08%, p<0.001) were found between before and during CRT. Median rMTV(2.5) was 0.299 (range, 0 to 0.98) and median rTGA(2.5) was 0.209 (range, 0 to 0.92). During CRT, PET/CT detected newly developed distant metastasis in 1 patient, and this resulted in a treatment strategy change. At a median 4 months (range, 0 to 12 months) after completion of CRT, 8 patients (24.2%) achieved clinically complete response, 11 (33.3%) partial response, 5 (15.2%) stable disease, and 9 (27.3%) disease progression. SUV(max) (p = 0.029), rMTV(50%) (p = 0.016), rMTV(75%) (p = 0.023) on intra-treatment PET were found to correlate with complete clinical response. CONCLUSION: PET/CT during CRT can provide additional information useful for radiotherapy planning and offer the potential for tumor response evaluation during CRT. rMTV(50%) during CRT was found to be a useful predictor of clinical response. The Korean Society for Radiation Oncology 2014-03 2014-03-27 /pmc/articles/PMC3977129/ /pubmed/24724049 http://dx.doi.org/10.3857/roj.2014.32.1.31 Text en Copyright © 2014. The Korean Society for Radiation Oncology http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Seol, Ki Ho
Lee, Jeong Eun
PET/CT planning during chemoradiotherapy for esophageal cancer
title PET/CT planning during chemoradiotherapy for esophageal cancer
title_full PET/CT planning during chemoradiotherapy for esophageal cancer
title_fullStr PET/CT planning during chemoradiotherapy for esophageal cancer
title_full_unstemmed PET/CT planning during chemoradiotherapy for esophageal cancer
title_short PET/CT planning during chemoradiotherapy for esophageal cancer
title_sort pet/ct planning during chemoradiotherapy for esophageal cancer
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3977129/
https://www.ncbi.nlm.nih.gov/pubmed/24724049
http://dx.doi.org/10.3857/roj.2014.32.1.31
work_keys_str_mv AT seolkiho petctplanningduringchemoradiotherapyforesophagealcancer
AT leejeongeun petctplanningduringchemoradiotherapyforesophagealcancer